VRDN Q1 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98,000-54.6% YoY

Gross Profit

$98,000100.0% margin

Operating Income

-$72M-73952.0% margin

Net Income

-$68M-69541.8% margin

EPS (Diluted)

$-1.61

QoQ Revenue Growth

-6.7%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$387M

Total Liabilities

$36M

Stockholders' Equity

$351M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98,000	$216,000	-54.6%
Gross Profit	$98,000	-$18M	+100.6%
Operating Income	-$72M	-$26M	-179.9%
Net Income	-$68M	-$26M	-165.3%

Revenue Segments

Collaboration Revenue

$100,000100%